PARP inhibitors as first-line maintenance therapy in ovarian cancer: Update from SGO 2022
touchCONGRESS for touchONCOLOGY
Listen to Prof. Isabelle Ray-Coquard (France) cover key data presented at SGO 2022 on PARP inhibitors as first-line maintenance therapy in ovarian cancer, and their implications for clinical practice, including expert insights and interpretation from Dr Antonio González-Martín (Spain) and Dr Sandro Pignata (Italy).
OVERVIEW
INTERVIEW QUESTIONS
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from GlaxoSmithKline. This activity is provided by touchIME.
For further information visit our website: https://touchoncology.com/education/parp-inhibitors-maintenance-sgo2022/
Create your
podcast in
minutes
It is Free